These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34304373)

  • 1. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
    Kim ES; Keam SJ
    Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
    Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
    Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Wijnen B; Riemsma R; Fayter D; Armstrong N; Ahmadu C; Brandts L; Misso K; Kirwan JR; Kleijnen J; Joore MA
    Pharmacoeconomics; 2021 Dec; 39(12):1397-1410. PubMed ID: 34448148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
    Shimizu T; Kawashiri SY; Morimoto S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Kiya R; Sato S; Yamamoto H; Kawakami A
    Trials; 2023 Mar; 24(1):161. PubMed ID: 36869356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Filgotinib as rheumatoid arthritis therapy.
    Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
    Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating filgotinib for the treatment of rheumatoid arthritis.
    Richez C; Truchetet ME
    Expert Opin Pharmacother; 2021 Dec; 22(18):2435-2444. PubMed ID: 34402699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filgotinib: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2020 Dec; 80(18):1987-1997. PubMed ID: 33237566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
    Tanaka Y; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Combe BG; Kivitz AJ; Bae SC; Keystone EC; Nash P; Matzkies F; Bartok B; Pechonkina A; Kondo A; Ye L; Guo Y; Tasset C; Sundy JS; Takeuchi T
    Mod Rheumatol; 2022 Feb; 32(2):263-272. PubMed ID: 34910188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
    Westhovens R; Rigby WFC; van der Heijde D; Ching DWT; Stohl W; Kay J; Chopra A; Bartok B; Matzkies F; Yin Z; Guo Y; Tasset C; Sundy JS; Jahreis A; Mozaffarian N; Messina OD; Landewé RB; Atsumi T; Burmester GR
    Ann Rheum Dis; 2021 Jun; 80(6):727-738. PubMed ID: 33452004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
    Atsumi T; Tanaka Y; Matsubara T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Westhovens R; Ching DWT; Messina OD; Burmester GR; Bartok B; Pechonkina A; Kondo A; Yin Z; Guo Y; Tasset C; Sundy JS; Takeuchi T
    Mod Rheumatol; 2022 Feb; 32(2):273-283. PubMed ID: 34910203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Remission and Low Disease Activity Rates of Tofacitinib, Baricitinib, Upadacitinib, and Filgotinib versus Methotrexate in Patients with Disease-Modifying Antirheumatic Drug-Naive Rheumatoid Arthritis.
    Lee YH; Song GG
    Pharmacology; 2023; 108(6):589-598. PubMed ID: 37591216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
    Takeuchi T; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Genovese MC; Kalunian K; Walker D; Gottenberg JE; de Vlam K; Bartok B; Pechonkina A; Kondo A; Gao J; Guo Y; Tasset C; Sundy JS; Tanaka Y
    Mod Rheumatol; 2022 Jan; 32(1):59-67. PubMed ID: 33274687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.
    Aletaha D; Westhovens R; Gaujoux-Viala C; Adami G; Matsumoto A; Bird P; Messina OD; Buch MH; Bartok B; Yin Z; Guo Y; Hendrikx T; Burmester GR
    RMD Open; 2021 Aug; 7(2):. PubMed ID: 34385364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
    Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.